{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028343","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.768820+00:00","generated_at":"2026-05-31T19:41:44.422560+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient","bullets":["PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).","Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.","Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.","Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.","Patient remains alive; company plans to replicate results in ongoing Phase 3 study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028343","json":"https://secwatch.observer/filing/0001493152-24-028343.json","markdown":"https://secwatch.observer/filing/0001493152-24-028343.md","text":"https://secwatch.observer/filing/0001493152-24-028343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/0001493152-24-028343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:41:44.422560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}